



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/635, A61K 38/29		A1	(11) International Publication Number: WO 98/14478 (43) International Publication Date: 9 April 1998 (09.04.98)
<p>(21) International Application Number: PCT/US97/17216</p> <p>(22) International Filing Date: 25 September 1997 (25.09.97)</p> <p>(30) Priority Data: 08/724,539 30 September 1996 (30.09.96) US</p> <p>(71) Applicant (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CHOREV, Michael [IL/US]; Apartment 3, 1575 Beacon Street, Brookline, MA 02146 (US). ROSENBLATT, Michael [US/US]; 130 Lake Avenue, Newton Centre, MA 02159 (US).</p> <p>(74) Agent: TSAO, Y., Rocky; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: CONTINUOUS LOW-DOSE ADMINISTRATION OF PARATHYROID HORMONE OR ITS AGONIST</p> <p>(57) Abstract</p> <p>A method of promoting bone formation in a human patient, which includes the step of administering continuously to the patient parathyroid hormone or its agonist for a period of at least one month at a dosage between 10 and 400 units/24 hrs. Also disclosed are novel parathyroid hormone agonists.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

CONTINUOUS LOW-DOSE ADMINISTRATION
OF PARATHYROID HORMONE OR ITS AGONIST

CROSS REFERENCE TO RELATED APPLICATIONS

5 This application is a continuation-in-part of U.S. Patent Application Serial No. 08/359,293, filed December 19, 1994, now pending.

BACKGROUND OF THE INVENTION

Parathyroid hormone ("PTH") has been shown to 10 effect a positive bone balance (reviewed in Dempster, D.W. et al., Endocrine Rev., 1993, 14, 690-709; Riggs, L., Amer. J. Med., 1991, 91 (Suppl 5B), 37S-41S). The mammalian parathyroid hormone is a polypeptide product of the parathyroid glands. The mature circulating form of 15 the hormone is comprised of 84 amino acid residues.

Parathyroid hormone-related protein ("PTHrP") is a 139 to 20 173 amino acid-protein with N-terminal homology to PTH. PTHrP shares many of the biological effects of PTH including binding to a common PTH/PTHrP receptor (Schipani E., et al., Endocrinology, 1993, 132, 2157- 2165; Broadus, A.E., Steward, A.F., Parathyroid hormone-related protein: In: The Parathyroids, Bilezikian, J.P., Levine, M.A., Marcus R. Eds, Raven Press, NY. 1994, 259- 294).

25 The general efficacy of daily acute administration of PTH₁₋₈₄ and PTH₁₋₃₄ has been demonstrated in young, adult, and aged rats of both sexes (Dempster, D.W. et al., Endocrine Rev., 1993, 14, 690-709; Gunness-Hey, M., et al., Metab. Bone Dis. & Rel. Res., 1984, 5, 177-181), 30 as well as in other animal models, both normal and osteoporotic (Liu, C.C. et al., J. Bone Miner. Res., 1990, 5, 973-981; Podbesek, R., et al., Endocrinology, 1983, 112, 1000-1006). The anabolic effect of intermittently administered PTH is also observed in

- 2 -

osteoporotic men (Slovik, D.M., et al., J. Bone Miner. Res., 1986, 1, 377-381) and women (Reeve, J., et al., Br. Med. J., 1990, 301, 314-318) and with concurrent antiresorptive therapy (Hesch, R-D., et al. Calcif Tissue Int, 1989, 176-180) suggesting that the process is not coupled to active resorption. PTH₁₋₃₄ is a synthetic amino-terminal fragment of PTH₁₋₈₄ (Tregear, G.W., et al., Endocrinology, 1973, 93, 1349-1353; Mosekilde, L., et al., Endocrinology, 1991, 129, 421-428).

10 The mechanism for the anabolic effect of intermittent PTH is not entirely clear (Dempster, D.W. et al., Endocrine Rev., 1993, 14, 690-709). The effect is dose-dependent within a defined dose range. There is increase in net calcium absorption from the intestine, 15 and an increase in both calcium balance and calcium accretion into bone, with a corresponding increase in bone mass. This effect is also evident in the increase in trabecular bone forming surfaces and osteoblast number.

20 However, contrary to the demonstrated anabolic efficacy of daily subcutaneous injections of PTH, data from animal studies indicate that continuous administration (infusion) of the hormone either had no effect on bone growth or resulted in bone loss in dogs 25 (Podbesek, R., et al., Endocrinology, 1983, 112, 1000-1006; Malluche, H.H., et al., Am. J. Physiol., 1982, 242, F197-F202). Continuous administration of PTH has also been shown to inhibit osteoblast activity in humans. Simon, et al. (Simon, L.S., et al., J. Bone Miner. Res., 30 1988, 3, 241-246) examined the effects of intravenously infused hPTH₁₋₃₄ at a dose of 0.55 U/kg/hr (approximately 800 U over 24 hr) continuously for 24 hours in six osteoporotic subjects and two normal subjects. In all cases, serum levels of collagen type I, produced 35 principally by osteoblasts, decreased within 16 hours of

- 3 -

infusion, which also correlated with an increase in blood levels of ionized calcium.

SUMMARY OF THE INVENTION

The invention features a method of promoting bone formation in a human patient (e.g., a patient who suffers from osteoporosis). The method includes the steps of administering (e.g., transmucously, intravenously, transdermally, subcutaneously, via implantation, or via infusion) continuously to the patient PTH (mature form), 10 PTHrP, or an agonist thereof for a period of at least one month (as long as the life time of the patient, if necessary) at a dosage between 10 and 400 units/24 hrs.

PTH and PTHrP include, but are not limited to, human PTH (hPTH), human PTHrP (hPTHrP), bovine PTH 15 (bPTH), bovine PTHrP (bPTHrP), and rat PTH (rPTH). An agonist of PTH or PTHrP is a peptide which is a structural analog or fragment (preferably, an N-terminal fragment containing 50 or fewer amino acids) of a naturally occurring PTH or PTHrP and, like PTH and PTHrP, 20 also capable of binding to PTH receptor and, thereby, promoting bone formation. Examples of such an agonist include, but are not limited to, hPTH₁₋₃₄ NH₂, hPTH₁₋₃₉ NH₂, hPTH₁₋₄₄ NH₂, hPTH₁₋₆₈ NH₂, [Nle^{8,18}, Tyr³⁴]hPTH₁₋₃₄ NH₂, bPTH₁₋₃₄ NH₂, [Nle^{8,18}, Tyr³⁴]bPTH₁₋₃₄, [Nle^{8,18}, Phe²², Tyr³⁴]bPTH₁₋₃₄ NH₂, 25 [Nle^{8,18}, Arg¹⁹, Tyr³⁴]bPTH₁₋₃₄ NH₂, [Nle^{8,18}, Arg²¹, Tyr³⁴]bPTH₁₋₃₄ NH₂, or [Nle^{8,18}, Arg^{19,21}, Tyr³⁴]bPTH₁₋₃₄ NH₂. The symbol NH₂ denotes amidation of the carboxyl group (-CO·OH) of the C-terminal amino acid to form -CO·NH₂. The following publications disclose the sequences of PTH peptides: The 30 Parathyroids Basic and Clinical Concepts, ed. John P. Bilezikian, 239-258 (Raven Press, NH 1994); Nissensohn, R., et al., Structure & Function of the Receptor for Parathyroid Hormone and Parathyroid Hormone-Releasing Hormone, 3 Receptor 193-202 1993; Bachem California 1993-

- 4 -

1994 Catalog (Torrance, CA); and Sigma Peptides and Amino Acids 1994 Catalog (St. Louis, MO). The following publications disclose the sequences of PTHrP peptides:
Yasuda, et al., 264 J. Biol. Chem. 7720-7725 (1989);
5 Schermer, D.T., Journal of Bone & Mineral Research 6:149-155 (1991) and Burtis, W.J., 38(11) Clinical Chemistry 2171-2183 (1992). More examples can be found in the following publications:

- 10 German Application 4203040 A1 (1993);
PCT Application 94/01460 (1994);
PCT Application 94/02510 (1994);
EP Application 477885 A2(1992);
EP Application 561412 A1 (1993);
PCT Application 93/20203 (1993);
15 U.S. Patent No. 4,771,124 (1988);
PCT Application 92/11286 (1992);
PCT Application 93/06846 (1993);
PCT Application 92/10515 (1992);
U.S. Patent No. 4,656,250 (1987);
20 EP Application 293158 A2 (1988);
PCT Application 94/03201 (1994);
EP Application 451,867 A1 (1991);
US Patent No. 5,229,489 (1993); and
PCT Application 92/00753 (1992).
25 Note that partial PTH agonists can also be used to practice the method of this invention. Examples of partial PTH agonists include, but are not limited to, N-terminal deletion analogs (e.g., [Tyr³⁴]bPTH₁₋₃₄ NH₂; see U.S. Patent No. 4,771,124 (1988)).

- 5 -

Preferred ranges of dosages include 10-300 units/24 hrs, 10-200 units/24 hrs, 10-100 units/24 hrs, 100-400 units/24 hrs, 200-400 units/24 hrs, and 300-400 units/24 hrs.

5 One unit of PTH, PTHrP, or an agonist thereof is defined by utilizing an *in vitro* cAMP accumulation assay with human SaOS-2 cells. Human SaOS-2 cells respond upon exposure to PTH, PTHrP, or an agonist thereof with a dose-dependent stimulation of cAMP accumulation. With
10 [Nle^{8,18},Tyr³⁴]hPTH₁₋₃₄ NH₂ as the reference standard analog (10,000 units/mg), a dose-response relationship can be generated using standard non-linear regression analysis. The relative potency for various PTH analogs (in units/mg) can be determined from the ratio of the EC₅₀ of
15 the reference standard analog to that of the PTH analog. EC₅₀ is defined as the dose that evokes a half maximal response -- cAMP accumulation herein. The detailed procedure for handling the cells, setting up the assay, as well as methods for cAMP quantitation, is described in
20 Sistane, E., et al., Pharmacopeial Forum 20(3), 7509-7520 (1994).

If the administration is to be achieved via infusion, an ambulatory (e.g., MINIMED™ 404-SP, MiniMed Technologies, Sylmar, CA; Pharmacia Deltec CADD-MICRO
25 MODEL™ S900, Pharmacia Deltec Inc., St. Paul, MN; or Disetronic Medical System's PANOMAT™, Plymouth, MN) or an implantable pump (e.g., MEDTRONIC SYNCROMED™, Medtronic, Inc., Minneapolis, MN) can be used.

Preferably, PTH, PTHrP, or an agonist thereof is
30 administered as a sustained release formulation. As an example, the formulation may contain a homo- or a co-polymer prepared from lactic acid (D-isomer, L-isomer, or a racemate), glycolide, glycolic acid, caprolactone, or lactide.

- 6 -

Examples of suitable sustained release formulations can be found in the following publications:

5 U.S. Patent No. 3,773,919 (1973);
 U.S. Patent No. 5,187,150 (1993);
 U.S. Patent No. 4,767,628 (1988);
 U.S. Patent No. 4,675,189 (1987);
 U.S. Patent No. 5,271,945 (1993);
 U.S. Patent No. 4,917,893 (1990); and
 U.S. Patent No. 3,887,699 (1975).

10 The sustained release formulations can be administered parenterally (e.g. subcutaneously, or intravenously) or by inhalation (e.g. using an aerosol delivery system; e.g., see WO93/00951 and WO94/07514).

15 In other embodiments, PTH, PTHrP, or an agonist thereof can be administered transmucosally (e.g. nasal, vaginal, rectal) or transdermally (e.g. iontophoretic patch).


20 Also, if desired, a bone resorption inhibiting agent can also be administered during performance of the above described method. The term "inhibition of bone resorption" refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or metabolism. Thus, the term "inhibitor of bone resorption" as used herein refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or metabolism. An example of suitable bone resorption inhibiting agents includes, but 25 is not limited to, an estrogen, a bisphosphonate, sodium fluoride, a tamoxifen, vitamin D, and calcium. See U.S. Patent No. 5,118,667 (1992).

30 The preferred dose and duration for practicing the above-described method varies depending upon the manner of administration, the age and the body weight of the

- 7 -

subject and the condition of the subject to be treated, and ultimately will be decided by the attending physician. The formulations may conveniently be presented in unit dosage form and may be prepared by any 5 of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient(s) into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations for tablets or powders are 10 prepared by uniformly and intimately blending the active ingredient (e.g., hPTH) with finely divided solid carriers, and then, if necessary as in the case of tablets, forming the product into the desired shape and size.

15 The invention also features novel PTH or PTHrP agonists of the following formula:



wherein:

25 A₁ is Ser or Ala;
A, is Leu or Phe;
A₁₂ is Gly, Aib, Ala, or D-Ala;
A₁₆ is Asn, Ser or Ala;
A₁₉ is Glu, Arg, Lys, Asp, Ser, Thr, Gln, Asn, or
30 Ala;
A₂₁ is Val, Met, Arg, Lys, Glu, Asp, Ser, Thr,
Gln, Asn, Leu, Ile, Nle, Ala, Phe, or p-X-Phe where X is
OH, CH₃, NO₂, or a halogen;

- 8 -

A₂₂ is Glu, Asp, Phe, p-X-Phe where X is OH, CH₃, NO₂ or a halogen, Ser, Thr, Gln, Asn, Leu, Ile, Nle, Val, Ala, or Met;

A₂₃ is Trp, 1-Nal, or 2-Nal;

5 A₃₄ is Phe, or p-X-Phe where X is OH, CH₃, NO₂, or a halogen;

W is OH, C₁₋₁₂ alkoxy, C₇₋₂₀ phenylalkoxy, C₁₁₋₂₀ napthylalkoxy, or NR₄; provided that when A₁₂ is Gly, A₁₉ is Glu, A₂₁ is Val, and A₂₂ is Gln, then A₂₃ must be 1-Nal 10 or 2-Nal; and

each of R₁, R₂, R₃, and R₄ is, independently, H, C₁₋₁₂ alkyl, C₇₋₁₀ phenylalkyl, or CO-E where E is C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, phenyl, naphthyl, or C₇₋₂₀ phenylalkyl; or a pharmaceutically acceptable salt 15 thereof.

In the above formula, the N-terminus is at the left and the C-terminus at the right in accordance with the conventional representation of a polypeptide chain. Also, The symbol A₁, Val, A,, or the like in a peptide 20 sequence stands for an amino acid residue, i.e., =N-CH(R)-CO- when it is at the N-terminus or -NH-CH(R)-CO- when it is not at the N-terminus, where R denotes the side chain of that amino acid residue. Thus, R is -CH(CH₃)₂ for Val. Also, when the amino acid residue is 25 optically active, it is the L-form configuration that is intended unless D-form is expressly designated. Further, the symbols Aib, 1-Nal, and 2-Nal herein are abbreviations for α -aminoisobutyric acid, 3-(1-naphthyl) alanine, and 3-(2-naphthyl)alanine, respectively.

30 Preferred groups of compounds covered by the above formula include (i) those where A₁ is Ala; A, is Phe; and A₁₆ is Ser; (ii) those where A₁₉ is Glu or Arg; and A₂₁ is Val or Arg; and (iii) those where A₂₂ is p-X-Phe where X is OH, CH₃, NO₂, or a halogen. Below are particularly 35 preferred compounds: [Nle⁸⁻¹⁸,Arg¹⁹,Tyr³⁴]bPTH₁₋₃₄ NH₂,

- 9 -

[Nle^{8,18}, Arg²¹, Tyr³⁴]bPTH₁₋₃₄ NH₂, [Nle^{8,18}, Arg^{19,21}, Tyr³⁴]bPTH₁₋₃₄ NH₂, and [Nle^{8,18}, Phe²², Tyr³⁴]bPTH₁₋₃₄ NH₂. Such compounds, as PTH or PTHrP agonists, can be used to promote bone formation in a manner described above.

5 Other features and advantages of the present invention will be apparent from the following description of the preferred embodiments, and also from the appending claims.

DESCRIPTION OF PREFERRED EMBODIMENTS

10 The synthesis, selection and use of PTH, PTHrP or agonists thereof which are capable of promoting bone formation are within the ability of a person of ordinary skill in the art.

For example, well-known *in vitro* or *in vivo* assays
15 can be used to determine the efficacy of various PTH/PTHrP agonists to promote bone formation in human patients. For *in vitro* binding assays, osteoblast-like cells which are permanent cell lines with osteoblastic characteristics and possess receptors for PTH/PTHrP of
20 either rat or human origin can be used. Suitable osteoblast-like cells include ROS 17/2 (Jouishomme, H., et al., Endocrinology, 1992, 130, 53-60), UMR 106 (Fujimori, A., et al., Endocrinology, 1992, 130, 29-60) and the human derived SaOS-2 (Fukuyama, S., et al.,
25 Endocrinology, 1992, 131, 1757-1769). The cell lines are available from American Type Culture Collection, Rockville, Maryland, and can be maintained in standard specified growth media. Additionally, transfected human embryonic kidney cells (HEK 293) expressing the human PTC
30 receptor can also be utilized for *in vitro* binding assays. See Pines, et al., Endocrinology, 1994, 135, 1713-1716.

- 10 -

For *in vitro* functional assays, PTH and PTH-like agonist activities of peptide fragments or derivatives of parathyroid hormone or PTHrP can be tested by contacting a concentration range of the test compound with the cells 5 in culture and assessing the stimulation of the PTH/PTHrP receptors. Receptor stimulation is evidenced by the activation of second messenger molecules coupled to the receptors, for example, a stimulation of cyclic AMP accumulation in the cell or an increase in enzymatic 10 activity of protein kinase C, both of which are readily monitored by conventional assays (Jouishomme, H., et al., Endocrinology, 1992, 130, 53-60; Abou-Samra, A.B., et al., Endocrinology, 1989, 125, 2594-2599; Fujimori, A., et al., Endocrinology, 1991, 128, 3032-3039; Fukayama, 15 S., Et al., Endocrinology, 1994, 134, 1851-1858; Abou-Samra, A.B., et al., Endocrinology, 1991, 129, 2547-2554; and Pines, et al., Endocrinology, 1994, 135, 1713-1716). Other parameters of PTH action include increase in 20 cytosolic calcium and phosphoinositols, and biosynthesis of collagen, osteocalcin, and alteration in alkaline phosphatase activity.

PTH-like agonist activities of subfragments of PTH have been successfully analyzed by contacting peptides with rat kidney cells in culture and assessing cyclic AMP 25 accumulation (Blind, E., et al., Clin. Endocrinol., 1993, 101, 150-155) and the stimulation of 1,25-dehydroxyvitamin D₃ production (Janulis, M., et al., Endocrinology, 1993, 133, 713-719).

The following specific embodiments are, therefore, 30 to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Furthermore, all of the references cited in this disclosure are incorporated by reference.

- 11 -

Example 1

The PTH or PTHrP agonists of the invention were synthesized on an APPLIED BIOSYSTEMS™ 430A Automated Peptide Synthesizer (Applied Biosystems Inc., Foster City, CA) using version 1.40 of the software for NMP/HOBt Boc-based chemistry. The following side-chain protected amino acid derivatives were used in the course of the synthesis: N-Boc-Arg(N^G-Tosyl)-OH, N-Boc-Asp(cycHx)-OH, N-Boc-Glu(OBzl)-OH, N-Boc-His(Bom)-OH, N-Boc-Lys(Cl-Z)-OH, N-Boc-Ser(Bzl)-OH, N-Boc-Thr(Bzl)-OH, N-Boc-Tyr(Br-Z)-OH, and N-Boc-Trp(N'-For)-OH.

Cleavage from resin with concomitant removal of the side-chain protecting groups of pMBHA-R-bound peptide was performed by liquid HF in the presence of 10% anisole (20 mL/g resin-bound peptide) 1 hr at 0°C. Low-high HF procedures shall be used for cleavage from resin and deprotection for PTH agonists containing Trp. See Tam, et al., J. Am. Chem. Soc., 1983, 105, 6442. The resin-crude peptide mixture was washed with petroleum ether and ether. The dry resin-crude peptide mixture was extracted consecutively with 50% acetic acid and water. The combined washes were lyophilized. The lyophilized crude peptides were subjected to preparative RP-HPLC purification.

The full names for the abbreviations used above are as follows: Boc for t-butoxycarbonyl, For for formayl, cycHx for cyclohexyl, Cl-Z for 2-chlorobenzylloxycarbonyl, OBzl is O-benzyl, BOM for benzyloxymethyl, Bzl for benzyl, Br-Z for 2-bromo-benzyloxycarbonyl, N^G-Tosyl for tosyl at guanidyl site, and pMBHA-R for paramethoxybenzhydrylamine resin.

- 12 -

The crude peptides were purified on a WATERS DELTA PREP™ 4000 (Waters, Milford, MA), preparative HPLC system, connected to a PrepPack cartridge of Vydac™ C18 300A, 15-20 µm [47 x 300 mm] (Waters, Milford, MA) at a flow rate of 70 mL/min monitored at 220 nm. The analytical HPLC system included the following components: Waters 600E multisolvent delivery system, 490E programmable multiwavelength detector, 717 autosampler and a 747 data module. The samples were analyzed on a VYDAC™ C18 218TP5415 (150 x 4.6 mm, 5 µm), The Separation Group (Hesperia, CA) at a flow rate of 1 mL/min monitored at 220 nm. The solvent mixtures for both the analytical and preparative HPLC were: A: 0.1% TFA in H₂O, and B: 0.1% TFA in acetonitrile. The purity of the peptides and their derivatives exceeded 99% as determined from the analytical RP-HPLC.

The following four bovine PTH agonists were synthesized:

[Nle^{8.18},Phe²²,Tyr³⁴]bPTH₁₋₃₄ NH₂ (Analog I);
[Nle^{8.18},Arg¹⁹,Tyr³⁴]bPTH₁₋₃₄ NH₂ (Analog II);
[Nle^{8.18},Arg²¹,Tyr³⁴]bPTH₁₋₃₄ NH₂ (Analog III); and
[Nle^{8.18},Arg^{19,21},Tyr³⁴]bPTH₁₋₃₄ NH₂ (Analog IV).

These four analogs were analyzed using HPLC (gradient of 30 min) and the results are shown in Table I below. For each solvent gradient, only the intitial and final percentages of B of the solvent (which consists of both A and B -- see above for their compositions) are indicated.

- 13 -

TABLE I

ANALOG	RETENTION TIME (min.)	SOLVENT GRADIENT (%)
I	20.6	25 - 45
II	14.2	25 - 50
III	13.6	25 - 50
IV	17.1	20 - 50

5

The results of the amino acid analysis of the four analogs are shown in Table II below, which lists both calculated and found values.

- 14 -

TABLE II

Amino Acid		Analog I	Analog II	Analog III	Analog IV
Asx	Calcd.	3.00	3.00	3.00	3.00
	Found	3.23	3.09	3.16	3.22
Ser	Calcd.	3.00	3.00	3.00	3.00
	Found	2.75	2.54	2.48	2.86
Glx	Calcd.	4.00	4.00	5.00	4.00
	Found	4.27	4.27	5.35	4.34
Gly	Calcd.	1.00	1.00	1.00	1.00
	Found	1.03	1.08	1.01	1.07
Ala	Calcd.	1.00	1.00	1.00	1.00
	Found	1.04	1.03	0.97	0.95
Val	Calcd.	3.00	3.00	2.00	2.00
	Found	2.80	3.03	1.97	1.68
Ile	Calcd.	1.00	1.00	1.00	1.00
	Found	0.99	.096	0.91	0.81
Leu	Calcd.	4.00	4.00	4.00	4.00
	Found	4.24	4.32	4.11	4.25
Nle	Calcd.	2.00	2.00	2.00	2.00
	Found	1.61	1.50	1.94	2.19
Tyr	Calcd.	1.00	1.00	1.00	1.00
	Found	1.15	1.06	1.01	1.10
Phe	Calcd.	2.00	1.00	1.00	1.00
	Found	2.06	0.97	1.00	0.93
His	Calcd.	3.00	3.00	3.00	3.00
	Found	2.85	3.03	2.93	2.64
Lys	Calcd.	3.00	3.00	3.00	3.00
	Found	3.00	2.93	3.05	2.90
Arg	Calcd.	2.00	3.00	3.00	4.00
	Found	1.97	3.20	3.11	4.04

Table III demonstrates the FAB (fast-atom bombardment) mass spectrometer analysis of the analogs.

- 15 -

TABLE III

ANALOG	MEASURED	PREDICTED
I	4106.8	4105.8
II	4114.7	4114.8
III	4146.4	4144.8
IV	4173.5	4172.8

Example 2

SaOS-2 B10 cells were maintained in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) and 10 2 mM glutamine at 37°C in a humidified atmosphere of 5% CO₂ in air. The medium was changed every three or four days, and the cells were subcultured every week by trypsinization.

SaOs-2 B10 cells were maintained for four days 15 after they had reached confluence. The medium was replaced with 5% FBS RPS/1640 medium and incubated for 2 hrs at room temperature with 10 x 10⁴cpm mono-¹²⁵I-[Nle^{8,18}, Tyr³⁴(3-I¹²⁵)]bPTH₁₋₃₄ NH₂ in the presence or absence of a competing tested PTH agonist. The cells were washed 20 four times with ice-cold PBS and lysed with 0.1 M NaOH, and the radioactivity associated with the cells was counted in a scintillation counter. Synthesis of the radiolabelled [Nle^{8,18}. Tyr³⁴ (3-I¹²⁵)]bPTH₁₋₃₄NH₂ was carried out as described in Goldman ME et al., Endocrinology, 25 1988, 123, 1468-1475.

The binding assay was conducted on Analogs I-IV and Analog V (i.e., [Nle⁸, Nle¹⁸, Tyr³⁴]bPTH₁₋₃₄ NH₂). The IC₅₀'s (half maximal inhibition of binding of mono-¹²⁵I-[Nle^{8,18}, Tyr³⁴(3-I¹²⁵)]bPTH₁₋₃₄ NH₂) for the five tested 30 analogs were calculated and shown in Table IV below:

- 16 -

TABLE IV

ANALOG	IC ₅₀ (nM)
I	1.5
II	0.6
III	0.3
IV	0.3
V	1.5

5

Example 3

The adenylylate cyclase activity induced by each of
10 Analogs I-V was also measured in SaOS-2 B10 cells as
described previously (Rodan et al. 1983 J. Clin. Invest.
72;1511; Goldman et al. 1988 Endocrinology 123, 1468).
Confluent SaOS-2 B10 cells in 24 wells plates were
incubated 0.5 μ Ci [³H]adenine (26.9 Ci/mmol, New England
15 Nuclear, Boston, MA) in fresh medium at 37°C for 2 hrs,
and washed twice with Hank's solution. The cells were
treated with 1 mM IBMX [isobutylmethylxanthine, Sigma,
St. Louis, MO] in fresh medium for 15 min, and a tested
PTH analog was added to the medium to incubate for 5 min.
20 The reaction was stopped by the addition of 1.2 M TCA
followed by sample neutralization with 4 N KOH. Cyclic
AMP was isolated by the two-column chromatographic method
(see Salomon et al. 1974 Anal. Biochem. 58;541). The
radioactivity was counted in a scintillation counter
25 (Liquid scintillation counter 2200CA, PACKARD, Downers
Grove, IL). The EC₅₀'s (half maximal stimulation of
adenylylate cyclase) were calculated for the five PTH
analogs and are shown below:

- 17 -

TABLE V

ANALOG	EC ₅₀ (nM)
I	1.5
II	2.0
III	0.2
IV	0.5
V	2.0

5

Example 4

In vivo bone anabolic activities of PTH/PTHrP agonists are tested by administering the peptide or a formulation containing the peptide into intact animals or an experimental animal model of osteopenia. The animal model can be osteoporosis in rats induced by ovariectomy (Hori, M., et al., Bone Miner., 1988, 3, 193-199; Geral, 10 et al., J. Bone Miner. Res., 1989, 4, Suppl. 1, S303; Liu C-C. & Kalu, D.N., J. Bone Miner. Res., 1990, 5, 973-982; Mosekilde, L., et al., Endocrinol., 1991, 129, 421-428; Wronski, T.J., Yen C-F. Bone, 1994, 15, 51-58; Reviewed 15 in Demster D.W., et al., Endocrine Rev., 1993, 14, 690-699). 20

The bone anabolic effects of the compound are determined following 12 to 60 days of treatment by assessing the change in bone mineral density by dual energy x-ray absorptiometry or dry weight of femurs or 25 total ash weight (Hori, H., et al., Bone Miner., 1988, 3, 193-199; Hefti, E., et al., Clin. Sci., 1982, 62, 389-396). Increase in the rate of bone formation and mineralization are assessed using metabolic labels, e.g. tetracycline (Tam, C.S., et al., Endocrinology, 1982, 30 110, 506-512). Qualitative and quantitative evaluations of changes in trabecular/cortical bone volume and complexity are determined by standard histomorphometric methods (Wronski, T.J., Yet C-F, Bone, 1994, 15, 51-58;

- 18 -

Tam C.S., et al., Endocrinology, 1982, 110, 506-612;
Podbesek, R., et al., Endocrinology 1983, 112, 1000-1006)
of bone samples from control (untreated) and treated
animals.

5 Example 5

The anabolic efficacy of the PTH/PTHrP agonists are tested in humans (Review in Dempster D.W., et al., Endocrine Rev., 1993, 14, 690-709). To determine if continuous administration of hPTH₁₋₃₄ or its agonist is effective in promoting bone growth in humans, 30 post-menopausal women with established osteoporosis based on bone-density measurements are selected. A double-blind, placebo-controlled, randomized experiment is conducted where two groups of 15 women each are either placed on placebo treatment or continuous infusion of a defined dose of hPTH₁₋₃₄ (25 units to 400 units/24 hrs) using an infusion pump.

The patients prior to the study are subject to the following: complete health and physical examination, evaluation of the nutritional status (particularly of calcium intake and serum calcium), full analysis of biomarkers for bone-turnover (Riis, B.J., Amer. J. Med. 1993, 95 [Suppl 5A], 17s-21s; Delmas, P.D., Amer. J. Med., 1991, 91 [Suppl 5B], 59s-63s), radiology, bone mass measurements of vertebral and axial sites (Gerant, H.K., et al., Amer. J. Med., 1991, 91 [Suppl 5B], 49s-53s; Wasnich, R.D., Amer J Med, 1991, 91 [Suppl 5B], 54s-58s) and bone biopsy, to establish the baseline parameters for each individual. After one and three months of treatment, the patients are reevaluated for changes in serum calcium and biomarkers of bone turnover to determine the outcome of continuous hPTH₁₋₃₄ administration. When the biomarker analysis suggests an increase in osteoblast activity (e.g., increase in serum

- 19 -

alkaline phosphatase and serum osteocalcin), the treatments are extended to twelve months, wherein bone mass measurements and bone biopsy further provide clear indication of bone growth in the population treated with 5 continuous infusion hPTH₁₋₃₄.

OTHER EMBODIMENTS

From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit 10 and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

What is claimed is:

- 20 -

CLAIMS

1. A method of promoting bone formation in a human patient, said method comprising administering continuously to said patient PTH, PTHrP, or an agonist 5 thereof for a period of at least one month at a dosage between 10 and 400 units/24 hrs.

2. A method of claim 1, wherein said dosage is 10-300 units/24 hrs.

3. A method of claim 1, wherein said dosage is 10 10-200 units/24 hrs.

4. A method of claim 1, wherein said dosage is 10-100 units/24 hrs.

5. A method of claim 1, wherein said dosage is 100-400 units/24 hrs.

15 6. A method of claim 1, wherein said dosage is 200-400 units/24 hrs.

7. A method of claim 1, wherein said dosage is 300-400 units/24 hrs.

8. A method of claim 1, wherein said agonist is 20 hPTH₁₋₃₄ NH₂ or [Nle^{8,18}, Tyr³⁴]hPTH₁₋₃₄ NH₂.

9. A method of claim 1, wherein said agonist is bPTH₁₋₃₄ NH₂, [Nle^{8,18}, Tyr³⁴]bPTH₁₋₃₄ NH₂, [Nle^{8,18}, Phe²²,
Tyr³⁴]bPTH₁₋₃₄ NH₂, [Nle^{8,18}, Arg¹⁹, Tyr³⁴]bPTH₁₋₃₄ NH₂,
[Nle^{8,18}, Arg²¹, Tyr³⁴]bPTH₁₋₃₄ NH₂, or [Nle^{8,18}, Arg^{19,21},
25 Tyr³⁴]bPTH₁₋₃₄ NH₂.

- 21 -

10. A method of claim 1, wherein infusion is performed to administer said PTH, PTHrP, or an agonist thereof.

11. A method of claim 10, wherein said infusion
5 is achieved with an ambulatory or implantable infusion pump.

12. A method of claim 1, wherein said PTH, PTHrP, or an agonist thereof is administered as a sustained release formulation.

10 13. A method of claim 12, wherein said sustained release formulation comprising a polymer prepared from lactic acid, caprolactone, glycolide, glycolic acid, or lactide.

14. A method of claim 1, further comprising the
15 step of administering to said patient a bone resorption inhibiting agent.

15. A method of claim 14, wherein said bone resorption inhibiting agent is a bisphosphonate.

16. A method of claim 14, wherein said bone
20 resorption inhibiting agent is a calcitonin.

17. A method of claim 14, wherein said bone resorption inhibiting agent is an estrogen.

18. A method of claim 12, further comprising the
step of administering to said patient a bone resorption
25 inhibiting agent.

- 22 -

19. A method of claim 18, wherein said bone resorption inhibiting agent is a bisphosphonate.

20. A method of claim 18, wherein said bone resorption inhibiting agent is a calcitonin.

5 21. A method of claim 18, wherein said bone resorption inhibiting agent is an estrogen.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/17216

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/635 A61K38/29

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 19246 A (BETH ISRAEL HOSPITAL ASSOCIATION) 27 June 1996 see the whole document ---	1-21
X	US 4 656 250 A (MORITA KAORU ET AL) 7 April 1987 see the whole document ---	1,8,9
A	WO 93 11786 A (PROCTER & GAMBLE PHARMA) 24 June 1993 ---	1-21
A	WO 94 02510 A (SANDOZ AG ;SANDOZ AG (DE); SANDOZ LTD (CH)) 3 February 1994 -----	1,14-21

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- A* document defining the general state of the art which is not considered to be of particular relevance
- E* earlier document but published on or after the international filing date
- L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- O* document referring to an oral disclosure, use, exhibition or other means
- P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

1

Date of the actual completion of the international search

30 January 1998

Date of mailing of the international search report

20.02.98

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Donath, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/US 97/17216

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9619246 A	27-06-96	AU 4472896 A EP 0800405 A	10-07-96 15-10-97
US 4656250 A	07-04-87	JP 1684818 C JP 3052479 B JP 60034996 A JP 61024598 A DE 3428942 A FR 2550204 A	31-07-92 12-08-91 22-02-85 03-02-86 28-02-85 08-02-85
WO 9311786 A	24-06-93	AU 663348 B AU 3022692 A AU 3322593 A BR 9206941 A CA 2124792 A CZ 9401477 A EP 0618805 A FI 942884 A HU 68010 A JP 7502507 T MX 9207349 A NO 942241 A NZ 246456 A SK 74594 A US 5616560 A ZA 9209758 A	05-10-95 24-06-93 19-07-93 02-05-95 24-06-93 15-12-94 12-10-94 16-06-94 29-05-95 16-03-95 01-12-93 09-08-94 24-03-97 05-01-95 01-04-97 10-09-93
WO 9402510 A	03-02-94	AU 4156693 A CA 2100423 A CH 688195 A CN 1099801 A CZ 9500088 A DE 4393381 T EP 0672057 A FI 950171 A GB 2269176 A,B HU 70459 A HU 9500320 A IL 106326 A JP 6184198 A	20-01-94 16-01-94 13-06-97 08-03-95 18-10-95 27-04-95 20-09-95 13-03-95 02-02-94 30-10-95 30-10-95 30-09-97 05-07-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/US 97/17216

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9402510 A		MX 9304251 A NO 950123 A NZ 248137 A SK 4395 A ZA 9305126 A	28-02-94 15-03-95 21-12-95 07-06-95 16-01-95

